MedTrace Logo

An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device (bRIGHT)

NCT04483089 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 511

Last updated 2026-05-18

No results posted yet for this study

Summary

The bRIGHT EU PAS study is an observational real-world study evaluating severe tricuspid regurgitation patients treated with the Abbott TriClip™ device (bRIGHT EU Post-Approval Study).

Conditions

  • Tricuspid Valve Regurgitation

Interventions

DEVICE

Transcatheter heart valve procedure

Transcatheter treatment of TR with Abbott TriClip™.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Meghan Griffin · Clinical Program Director

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-27
Primary Completion
2027-12-31
Completion
2028-01-31
FDA Device
Yes

Countries

  • Austria
  • Denmark
  • Germany
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483089 on ClinicalTrials.gov